Eupraxia Pharmaceuticals' (EPRX) Buy Rating Reiterated at HC Wainwright

Key Points

• HC Wainwright reiterated a Buy rating on Eupraxia with an $11 price target, implying roughly a 45.7% upside from Monday's close near $7.55.
• Analyst views are mixed—Cantor Fitzgerald raised its target to $19 (overweight) while Zacks and Weiss issued sell-type calls—yet MarketBeat shows a consensus of Moderate Buy with an average target of $15.
• Fundamentals remain challenging: Eupraxia missed Q1 with EPS of ($0.37) versus an expected ($0.16) and analysts forecast about ($0.73) EPS for the year; the company has a market cap near $456 million and a 52‑week range of $3.67–$9.32.

Eupraxia Pharmaceuticals (NASDAQ:EPRX - Get Free Report)'s stock had its "buy" rating restated by stock analysts at HC Wainwright in a research note issued on Monday,Benzinga reports. They currently have a $11.00 target price on the stock. HC Wainwright's target price would indicate a potential upside of 45.70% from the stock's previous close.

A number of other analysts have also commented on the stock. Zacks Research lowered shares of Eupraxia Pharmaceuticals from a "hold" rating to a "strong sell" rating in a research note on Tuesday, March 17th. Cantor Fitzgerald upped their price objective on shares of Eupraxia Pharmaceuticals from $11.00 to $19.00 and gave the company an "overweight" rating in a research note on Thursday, January 15th. Wall Street Zen raised shares of Eupraxia Pharmaceuticals from a "strong sell" rating to a "sell" rating in a research note on Saturday, April 18th. William Blair started coverage on shares of Eupraxia Pharmaceuticals in a research note on Monday, March 23rd. They set an "outperform" rating for the company. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Eupraxia Pharmaceuticals in a research note on Tuesday, April 21st. Two investment analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating and two have assigned a Sell rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $15.00.

Eupraxia Pharmaceuticals Stock Performance

Shares of NASDAQ:EPRX traded down $0.34 during trading hours on Monday, hitting $7.55. 48,504 shares of the company's stock traded hands, compared to its average volume of 210,713. Eupraxia Pharmaceuticals has a 52 week low of $3.67 and a 52 week high of $9.32. The company has a market cap of $456.25 million, a price-to-earnings ratio of -7.33 and a beta of 1.19. The company's fifty day simple moving average is $7.43 and its two-hundred day simple moving average is $7.19.

Eupraxia Pharmaceuticals (NASDAQ:EPRX - Get Free Report) last posted its quarterly earnings data on Thursday, March 19th. The company reported ($0.37) EPS for the quarter, missing analysts' consensus estimates of ($0.16) by ($0.21). On average, analysts anticipate that Eupraxia Pharmaceuticals will post -0.73 EPS for the current fiscal year.

Hedge Funds Weigh In On Eupraxia Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the company. Integrated Wealth Concepts LLC acquired a new position in Eupraxia Pharmaceuticals in the third quarter worth approximately $71,000. Bank of America Corp DE grew its holdings in Eupraxia Pharmaceuticals by 402.4% during the second quarter. Bank of America Corp DE now owns 12,559 shares of the company's stock valued at $72,000 after purchasing an additional 10,059 shares during the last quarter. Guardian Wealth Advisors LLC NC acquired a new position in Eupraxia Pharmaceuticals during the fourth quarter valued at approximately $76,000. Aptus Capital Advisors LLC acquired a new position in Eupraxia Pharmaceuticals in the 4th quarter valued at $76,000. Finally, Geode Capital Management LLC acquired a new position in Eupraxia Pharmaceuticals in the 4th quarter valued at $105,000.

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals, Inc NASDAQ: EPRX is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company's core strategy centers on selectively expanding regulatory T cells (Tregs)—immune cells responsible for maintaining self-tolerance and limiting pathological inflammation—through its proprietary platform. Its lead therapeutic candidate is currently in Phase 1 clinical development in patients with systemic lupus erythematosus.

Based in Seattle, Washington, Eupraxia Pharmaceuticals conducts research and development activities across North America, collaborating with academic institutions and contract research organizations to advance its pipeline.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.